

# Recombinant Mouse CD70 Protein(His Tag)

Catalog Number: PDMM100063

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


## Description

<b>Species</b>	Mouse
<b>Source</b>	Mammalian-derived Mouse CD70 protein Ser45-Ile193, with an an C-terminal His
<b>Mol_Mass</b>	16.2 kDa
<b>Accession</b>	O55237
<b>Bio-activity</b>	Not validated for activity

## Properties

<b>Purity</b>	> 90% as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	< 1.0 EU/mg of the protein as determined by the LAL method
<b>Storage</b>	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
<b>Shipping</b>	This product is provided as lyophilized powder which is shipped with ice packs.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with 5% Trehalose and 5% Mannitol.
<b>Reconstitution</b>	It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

## Data



SDS-PAGE analysis of Mouse CD70 proteins, 2 µg/lane of Recombinant Mouse CD70 proteins was resolved with SDS-PAGE under reducing conditions, showing bands at 16.2 KD

## Background

CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T- and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have led to the identification of potential antibody-based clinical candidates.

## For Research Use Only